What Does the Research Say About Tysabri and PML?
From General Health Awareness to Specific Exposure Concerns
If you or a loved one is taking Tysabri and concerned about PML, you're likely wondering how the risk is assessed. Decades of pharmacovigilance and clinical research have established a clear link between Tysabri use and JC virus reactivation, leading to PML. This page reviews the published evidence on risk factors, monitoring strategies, and what the science says about early detection.
Understanding Tysabri and Its Link to PML
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three factors that increase the risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors must be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be subtle and variable, often including progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, and cognitive disorder among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they underscore the range of neurological symptoms that may be observed in patients on Tysabri and that could overlap with early PML manifestations.
Mechanism of PML Development and Risk Factors
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4 on lymphocytes, Tysabri prevents these immune cells from crossing the blood-brain barrier. This reduces central nervous system immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with detectable anti-JCV antibodies, as seropositivity indicates prior exposure to the virus. Duration of therapy beyond two years further amplifies risk, likely due to prolonged immunosuppression within the CNS. Given the severity of PML, the Tysabri label mandates that healthcare professionals monitor patients for any new sign or symptom suggestive of PML and withhold dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers to evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The program also mandates that prescribers determine every six months whether patients should continue treatment and submit status reports to Biogen. Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Statute of Limitations for Tysabri Claims in Texas
For patients in Texas who have developed PML after Tysabri exposure, attorney-related considerations include the statute of limitations for filing a product liability or personal injury claim. In Texas, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can be prolonged, as the disease may not become clinically apparent until months or years after the initiation of Tysabri therapy. The label notes that risk increases with treatment duration beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), meaning that patients may have been on the drug for an extended period before symptoms emerge. This latency period can complicate the determination of when the injury was discovered for statute of limitations purposes. Another critical risk anchor is the adequacy of warnings regarding Tysabri and PML. The boxed warning clearly states that Tysabri increases the risk of PML and lists the known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of anti-JCV antibody testing. The TOUCH program is designed to ensure that these warnings are communicated and that patients are monitored, but failures in program implementation or communication could form the basis of a claim that the warnings were inadequate.
Legal Evaluation and Next Steps
In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in the prescribing information. The clinical presentation of PML can be insidious, and the latency between exposure and harm may be prolonged. For affected patients in Texas, the statute of limitations for legal action is typically two years from discovery of the injury, but the timeline of PML development may affect when that clock starts. Attorney evaluation of individual cases should consider the adequacy of warnings, the patient's risk factors, and the timing of symptom onset relative to Tysabri exposure. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI)
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Texas?
In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, the latency period may affect when the clock starts, so it is important to consult an attorney promptly.
What are the risk factors for developing PML while on Tysabri?
The prescribing information identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.